Sales of the drug, which comprised nearly half of Merck’s sales last year, totaling $29.5 billion, are expected to peak ...

At a major cancer conference, Merck rolled out some showstoppers — data on drugs on which its business future may depend.

Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Trodelvy is being investigated for use in other TNBC and HR+/HER2- breast cancer populations, as well as a range of tumor types where Trop-2 is highly expressed, including extensive-stage small cell ...

Immutep ( ($IMMP) ) has shared an announcement. On October 20, 2025, Immutep Limited presented two posters at the ESMO Congress 2025, showcasing ...

Merck (MRK) announced new long-term data highlighting the sustained survival benefits of Keytruda, Merck’s anti-PD-1 therapy, in treating ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

Positive opinion also granted for KEYTRUDA as part of a perioperative regimen for the treatment of certain adult patients with resectable locally advanced head and neck squamous cell carcinoma ...